Science

Mar 12, 2025, 09:58

Myeloma Paper of the Day, March 12th, suggested by Robert Orlowski

Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Real-world experience of efficacy and safety of belantamab mafodotin in relapsed/refractory myeloma finds ORR and CR rates of 40.0 and 15.0%, median PFS and OS of 5 and 12 months.

However, this was all monotherapy and not with combos.”

“A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma”

Authors: Rachel Dileo, Prerna Mewawalla, Kalaivani Babu, Yue Yin, Christopher Strouse, Aliya Rashid, Bidushi Pokhrel, Nausheen Ahmed, Al-Ola Abdallah, Hamza Hashmi et al.

Myeloma Paper of the Day

More posts featuring Robert Orlowski.

Al-Ola Abdallah Aliya Rashid belantamab mafodotin Bidushi Pokhrel cancer Christopher Strouse Hamza Hashmi Kalaivani Babu multiple myeloma Myeloma Paper of the Day Nausheen Ahmed OncoDaily Oncology Prerna Mewawalla Rachel Dileo relapsed/refractory multiple myeloma Robert Orlowski RRMM Yue Yin

VERITAC-2 Trial Update: Vepdegestrant Meets Primary Endpoint in ESR1-Mutant Breast Cancer

New Paper Alert: HARMONi-2 study of Ivonescimab vs pembrolizumab for PD-L1-positive non-small cell lung cancer

We are thrilled to welcome Dr. Jasmine Kamboj to the OncoDaily Editorial Board!

Oncologist Near Me – Fedro Alessandro Peccatori: Leading Expert in Gynecological Oncology

MATTERHORN trial - FLOT plus durvalumab will become the new standard of care in the preoperative setting for gastroesophageal cancer